News | February 25, 2022
Risk appetite key to innovation in pharma and biopharma
Industry leaders discusses the need of innovation for the Indian drug industry at BioAsia 2022.
Industry leaders discusses the need of innovation for the Indian drug industry at BioAsia 2022.
It is a Phase 3 ready anti-myostatin adnectin for Spinal Muscular Atrophy (SMA).
Cataract is the most common cause of blindness in India, and that diabetes is to be blamed for the massive number of damaged eyes
Zerion´s innovative Dispersome technology builds on a new concept of increasing drug solubility by using natural protein-based excipients to formulate APIs into amorphous solid dispersions (ASDs) by spray drying
The 15-year agreement will leverage dedicated commercial fill-finish manufacturing capacity in the US for mRNA vaccines and therapies
Bangladesh, Indonesia, Pakistan, Serbia and Vietnam to receive mRNA technology from the technology transfer hub
The SureSTART consumables portfolio is designed for higher performance requirements, while meeting customer budgets
New expanded indication provides patients suffering from earlier stages of heart failure access to the CardioMEMS HF System, a small implantable sensor that can flag early warning signs of worsening heart failure
AIIA partners with Startup India with the aim to identify and support innovations and start-ups working in the Ayush sector
The COVID-19 pandemic has triggered the rapid growth of the biotherapeutics market
Subscribe To Our Newsletter & Stay Updated
